OncoMatch/Clinical Trials/NCT06415708
Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma
Is NCT06415708 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Obinutuzumab Combined With Bendamustine for b cell lymphoma.
Treatment: Obinutuzumab Combined With Bendamustine — This is a prospective, single-center, single-arm clinical study to evaluate the efficacy and safety of maintenance therapy with obinutuzumab for 2 years in patients ≥ 18 years of age with newly diagnosed mature B-cell lymphoma (including follicular lymphoma\[FL\], marginal zone cell lymphoma\[MZL\] , waldenström macroglobulinemia\[WM\], hairy-cell leukemia variant\[HCL-v\]) who achieved ≥ PR after 6 cycles of obinutuzumab in combination with bendamustine.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD20 positivity
histological documentation of CD20 positivity
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: chemotherapy
Mature B-cell lymphoma previously treated with chemotherapy, immunotherapy, or radiation therapy
Cannot have received: immunotherapy
Mature B-cell lymphoma previously treated with chemotherapy, immunotherapy, or radiation therapy
Cannot have received: radiation therapy
Mature B-cell lymphoma previously treated with chemotherapy, immunotherapy, or radiation therapy
Lab requirements
Blood counts
hemoglobin ≥ 7 g/dL; absolute neutrophil count ≥ 1.0 × 10^9/L; platelet count ≥ 50 × 10^9/L
Kidney function
creatinine clearance ≥ 30 mL/min
Liver function
AST or ALT ≤ 2.5 x ULN; Serum bilirubin ≤ 2 x ULN (≤ 3 x ULN for patients with Gilbert's syndrome)
Adequate blood function ... hemoglobin ≥ 7 g/dL absolute neutrophil count ≥ 1.0 × 10^9/L platelet count ≥ 50 × 10^9/L; Normal laboratory values: creatinine clearance ≥ 30 mL/min AST or ALT ≤ 2.5 x ULN Serum bilirubin ≤ 2 x ULN (≤ 3 x ULN for patients with Gilbert's syndrome)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06415708 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require CD20?
Yes, CD20 positivity is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages